Top Markets
#1 Islamic Coin Islamic Coin +154.32%
#2 PulseChain PulseChain +49.10%
#3 DogBull DogBull +34.89%
#4 BOOK OF MEME BOOK OF MEME +34.12%
#5 rsERG rsERG +20.54%
#6 Ergo Ergo +19.46%
#7 Bio Protocol Bio Protocol +16.01%
#8 Janction Janction +14.10%
#9 Victoria VR Victoria VR +13.92%
#10 RedStone RedStone +13.84%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM
Classifica tra le azioni #27180
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
Prezzo delle azioni
$1.10
Ultima sincronizzazione: 2026-08-19
Capitalizzazione di mercato
$34.64M
Variazione (1 giorno)
4.16%
Variazione (1 anno)
-32.68%
Paese
US
Scambia Actinium Pharmaceuticals, Inc. (ATNM)

Categoria

Healthcare
Storico del prezzo dell'azione per Actinium Pharmaceuticals, Inc. (ATNM)
Prezzo di chiusura più alto: $0.93 il 2026-08-01

Prezzo di chiusura più basso: $45.00 il 2012-12-01
Storico del prezzo dell'azione di Actinium Pharmaceuticals, Inc. dal 2012 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -14.63%
2025 18.85%
2024 -75.34%
2023 -52.01%
2022 60.20%
2021 -37.95%
2020 57.83%
2019 -47.21%
2018 -36.61%
2017 -30.98%
2016 -57.41%
2015 -60.88%
2014 -10.34%
2013 335.37%
2012 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $552.07 39.99%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $168.77 527.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 56.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $120.74 -14.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $756.93 6.35%
CH